GLP‐1RA offers several advantages over insulin therapy, including a lower risk of hypoglycaemia, significant weight loss and favourable effects on cardiovascular risk factors (including blood pressure and lipids) and cardiovascular and renal outcomes [10, 11]. Here, INS is linked to Hypoglycemia.